CapForce (OPGN) Q2 2024 earnings summary

Executive summary

• Revenue for Q2 2024 fell 96% year-over-year to $28,000, reflecting the deconsolidation of Curetis and Ares Genetics after their insolvency and the scaling down of operations while seeking strategic alternatives.

• Operating expenses dropped 73% year-over-year, driven by the absence of subsidiary costs and reduced headcount.

• The company completed a $3.0 million Series E Preferred Stock financing, with a change in control to AEI Capital Ltd. in August 2024.

• OpGen is exiting its Unyvero business and discontinued Ares Genetics products, focusing on a potential sale or reverse merger.

Financial highlights

• Q2 2024 revenue: $28,000, down from $736,137 in Q2 2023; six-month revenue: $196,149, down 88% year-over-year.

• Q2 2024 net loss: $1.58 million, improved from $5.83 million net loss in Q2 2023.

• Six-month net loss: $1.29 million, improved from $11.56 million loss in the prior year period.

• Operating expenses for Q2 2024: $1.58 million, down from $5.89 million in Q2 2023.

• Cash and cash equivalents at June 30, 2024: $0.2 million, with $2.16 million as of August 2024 after additional funding.

Outlook and guidance

• Management expects current cash to fund operations only into Q3 2024, with substantial doubt about the company's ability to continue as a going concern.

• The company is actively seeking additional funding or a strategic transaction; failure to secure either may result in ceasing operations or bankruptcy.